BPC-157: nitric oxide, angiogenesis, tendon-fibroblast outgrowth BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide first characterized by the Sikiric group at the University of Zagreb beginning in the early 1990s
There is no FDA-approved human trial
The male and female steady states
BPC-157 Peptide may be a suitable treatment for moderate chronic joint pain , tendon injuries, and other ailments, but it is best not to go it alone
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and did not provide support in the form of salaries for any authors
Red Fox Peptides ships from British Columbia to all Canadian provinces and territories